News

The first-in-class C5 complement inhibitor, Soliris has been indicated for anti-acetylcholine receptor antibody-positive children and adolescents aged six to 17 years. It is claimed to be the first

The start-up facilitates analytical and process development, CMC consulting as well as early-stage GMP manufacturing of cell therapies. Initially, its emphasis will be on manufacturing immune cell therapies, such

To be spread over a 69,000ft2 area, the expanded production unit will feature innovative technologies and equipment that aid in developing, producing and analysing advanced therapy medicinal products (ATMP). The

Overland ADCT BioPharma is a joint venture between Overland Pharmaceuticals and ADC Therapeutics. This therapy is seeking an indication to treat adults with relapsed or refractory (r/r) diffuse

The therapy is intended for adults and adolescents aged 12 years and above. This recommendation will be forwarded to the European Commission (EC), which will make a final

Earlier known as AV7909, CYFENDUS vaccine’s efficacy for post-exposure prophylaxis is only based on studies in animal models of inhalational anthrax. Emergent senior vice president, science and development

ORLADEYO (berotralstat) is claimed to be the first and only oral treatment intended particularly to prevent attacks of hereditary angioedema (HAE) in adult and paediatric patients aged 12 years

The US products are FLAREX, NATACYN, TOBRADEX, VERKAZIA, ZERVIATE, FRESHKOTE, while the Canadian products are VERKAZIA, Cationorm PLUS. FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for treating steroid-responsive

Under the collaboration, the companies will leverage Eleven’s DELiveri platform that uses DNA-encoded libraries (DELs), for identifying new molecules that promote precise nucleic acid delivery for treating cardiometabolic